<DOC>
	<DOC>NCT00668070</DOC>
	<brief_summary>The aim of this study is to explore the effect of a new drug (ASP9831) in patients with non-alcoholic steatohepatitis (NASH) by assessing clinical signs, laboratory data and biomarkers during a 12 week treatment period</brief_summary>
	<brief_title>A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9831</brief_title>
	<detailed_description>The study includes an open-label sub-study prior to the main study</detailed_description>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Phosphodiesterase 4 Inhibitors</mesh_term>
	<criteria>NASH, histologically confirmed by a liver biopsy performed within 1 year prior to first dose and randomization Elevated serum ALT levels Hepatic cirrhosis Other known cause of liver disease Uncontrolled diabetes mellitis type 2, i.e. HbA1c &gt; 8.5% Positive history of tuberculosis or a positive PPD skin test which is not explained by previous BCG vaccination History of excessive alcohol abuse within 5 years prior to screening or a current average alcohol intake of more than 20 g/day (2 units) for females or more than 30 g/day (3 units) for males Subject has used drugs associated with steatohepatitis within 6 months prior to screening (corticosteroids, high dose estrogens, methotrexate, amiodarone, antiHIV drugs, tamoxifen)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
	<keyword>NASH</keyword>
	<keyword>Chronic liver disease</keyword>
</DOC>